Correlation of Indoleamine-2,3-Dioxygenase and Chronic Kidney Disease: A Pilot Study
Binbin Pan, Feng Zhang, Jian Sun and 5 more
Journal of Immunology Research · 2021
doi:10.1155/2021/8132569 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Objective. To explore the correlation of indoleamine-2,3-dioxygenase (IDO) and chronic kidney disease (CKD). Methods. A total of 154 CKD patients and 42 non-CKD patients were recruited. Patients were grouped into ACR1~ACR3 (<30 mg/g, 30-300 mg/g, and >300 mg/g). Biomarkers in different groups were compared by ANOVA. Correlation was calculated by Pearson or Spearman analysis and binary logistic regression. The ROC curve was also performed. Results. The levels of albumin, serum creatinine (sCr), and IDO in non-CKD patients were significantly different from those in CKD3-CKD5 stages (p<0.05). IDO was correlated with age, proteinuria, ACR, and eGFR (p<0.01). After adjusting for CKD-related indices, ln(IDO) was an independent risk factor for CKD (3.48, p<0.05). The analysis of ROC curve revealed a best cutoff for IDO was 0.0466 and yielded a sensitivity of 83.8% and a specificity of 75%. Hemoglobin, total protein, and albumin in the ACR1 group were significantly higher than those in the ACR2 and ACR3 groups (p<0.01), while sCr and IDO levels were significantly lower than those in the ACR2 and ACR3 groups (p<0.01 or p<0.05). After adjusting for CKD-related indices, ln(IDO) was still an independent risk factor for ACR (OR=2.7, p<0.05). The analysis of ROC curve revealed a best cutoff for IDO was 0.075 and yielded a sensitivity of 71.9% and a specificity of 72.2%. Conclusion. IDO may be a promising biomarker to predict CKD and assess kidney function.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.